12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Yervoy ipilimumab regulatory update

Germany's Federal Joint Committee (G-BA) said Yervoy from Bristol-Myers Squibb provides an "important additional benefit" over best supportive care in patients with advanced malignant melanoma who have received previous therapy. Best supportive care consists of...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >